Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Ophthalmology

Articles with lock require a GLG News subscription
Robert Devenyi Posted February 15, 2007
Genentech has a huge problem with their credibility
Analysis of: Dear Doctor Letter regarding Lucentis | www.gene.com
Author: Robert Devenyi, Professor and Chief of Ophthalmology University of Toronto
Genentech should have voluntarily compared Lucentis with Avastin.All of Genentech's efforts to promote Lucentis seem self serving and insincere.
Barry Schechter Posted February 14, 2007
ISTA takes the lead in topical NSAID therapy
Analysis of: ISTA Pharmaceuticals Announces Positive Preliminary Xibrom Once-daily Formulation Clinical Results From U.S. Phase III Trials | pharmalive.com
Author: Barry Schechter, Director of Corneal and External Diseases Florida Eye Microsurgical Institute, Inc.
There has been a sea change in the treatment of postoperative cataract patients. The addition of a nonsteroidal has significantly reduced postoperative complications such as edema, discomfort and inflammation.Compliance with all medications is always an issue, and the use of a once daily medication...
Posted January 25, 2007
Cooper Continues to Have Prolems With the Launch of Its Silicone Hydrogel Lenses
Analysis of: Cooper gets S&P rating downgrade | www.businessweek.com
Author: Darcy Ryan, Optometrist Hertzog Eye Associates
Cooper continues to lag behind the competition in the silicone hydrogel market.  They still haven't had a large scale launch of its Biofinity lens and there's no date set.Cooper's lenses have been a staple in my office since I started practicing, but as I transition my patients in the healthier...
Posted January 24, 2007
Selective use of anti-TNFs
Analysis of: Infliximab, Adalimumab Reduce Uveitis Flares in Spondylarthropathy | www.medscape.com
Author: GLG Member Program Contributor
Helps differentiate use of anti-TNF drugs - use monoclonals for Uveitis associated with rheumatological diseases.
Sanjay Rao Posted January 18, 2007
Scleral expansion: A legitimate contender in the presbyobia arena?
Analysis of: Scleral spacing procedures investigated for presbyopia | www.ophthalmologytimes.com
Author: Sanjay Rao, Medical Director Lakeside Eye Clinic
This article describes the Phase II trial results of the PreView Scleral Implants (ReFocus Group Inc.) for the treatment of presbyopia.  Presbyopia is the natural age related loss of accommodation, or near focusing ability that leads to people wearing reading glasses. Scleral implants alter the...
Sanjay Rao Posted January 10, 2007
AMO's Acquisition of Intralase: A clinician's perspective
Analysis of: AMO's IntraLase Acquisition Applauded By Analysts | www.forbes.com
Author: Sanjay Rao, Medical Director Lakeside Eye Clinic
AMO's acquisition of Intralase for $808 million has been seen by most financial industry analysts as positive.  Most financial analysts point to the improved diversification and strengthening of AMO's refractive portfolio which includes intraocular lenses, phacoemulsification equipment, VISX excimer...
Posted January 9, 2007
BIGGEST NEWS OF 2007: AMO to Purchase Intralase
Analysis of: Advanced Medical Optics to Acquire IntraLase Corp. | biz.yahoo.com
Author: GLG Member Program Contributor
It is reported today that AMO will purchase Intralase Corp for 808 million dollars in what could securely position AMO as the world leader in all aspects of LASIK and laser vision correction technology. For months it has been speculated that such a purchase would occur.
Posted January 4, 2007
Use of Intacs Limited to Treatment of Corneal Ectasias
Analysis of: Long-term Follow-up of Intacs for Post-LASIK Corneal Ectasia | www.sciencedirect.com
Author: GLG Member Program Contributor
While the use of Intacs has practically ended for routine correction of myopia, and the company management and ownership has shifted several times in the last few years, there has been a great interest and success in using these implants for the stabilization of eyes with ectasias such as keratoconus...
Sanjay Rao Posted January 3, 2007
The next LASIK procedure?
Analysis of: SBK will be next trend in laser refractive surgery | www.osnsupersite.com
Author: Sanjay Rao, Medical Director Lakeside Eye Clinic
This article describes the results of a "newer" refractive surgery technique known as sub-Bowman's keratomileusis or SBK.  SBK involves creating a corneal flap just below the epithelial layer of the cornea.  This flap is approximately 60-70 microns in thickness compared to a traditional...
Posted January 3, 2007
Bepotastine has novel mechanism of action but clinical results are still pending
Analysis of: ISTA Pharmaceuticals Submits Investigational New Drug Application For Eye Drop For The Treatment Of Allergic Conjunctivitis | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Bepotastine eye drops has 3 mechanisms of action to potentially treat allergic conjunctivitis.Its clinical development is still early and it needs to show superiority to current available mast cell stabilizers.One potential competitive advantage would be once daily administration.
Previous Page : 10 11 12 13 14 15 16 17 18 19 20 21 22 Next191 to 200 of 220

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-11-21T13:45:47.600